$SLRX
Salarius Pharmaceuticals, Inc.

2018 Q2 Form 10-Q Financial Statement

#000161521918000032 Filed on May 02, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2018 Q1 2017 Q1
Revenue $245.5K $178.6K $242.5K
YoY Change -26.83% -26.37%
Cost Of Revenue $179.9K $83.93K $79.11K
YoY Change 23.82% 6.1% -59.85%
Gross Profit $65.56K $94.65K $163.4K
YoY Change -65.53% -42.09% -182.96%
Gross Profit Margin 26.7% 53.0% 67.39%
Selling, General & Admin $2.780M $3.700M $4.590M
YoY Change -44.29% -19.39% -10.18%
% of Gross Profit 4240.58% 3909.22% 2808.35%
Research & Development $6.175M $4.680M $3.915M
YoY Change 51.48% 19.55% -10.76%
% of Gross Profit 9418.66% 4944.83% 2395.34%
Depreciation & Amortization $60.00K $64.07K $91.37K
YoY Change -25.0% -29.88% 196.52%
% of Gross Profit 91.52% 67.69% 55.9%
Operating Expenses $9.349M $8.461M $8.589M
YoY Change 1.48% -1.48% -11.42%
Operating Profit -$9.104M -$8.283M -$8.346M
YoY Change 2.55% -0.76% -13.92%
Interest Expense $50.00K $60.00K $80.00K
YoY Change -28.57% -25.0% -20.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$9.050M -$8.220M -$8.270M
YoY Change 2.84% -0.6% -14.71%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings $111.2K -$381.5K -$8.268M
YoY Change -101.26% -95.39% -13.8%
Net Earnings / Revenue 45.31% -213.65% -3408.99%
Basic Earnings Per Share
Diluted Earnings Per Share -$12.57M -$11.42M -$12.34M
COMMON SHARES
Basic Shares Outstanding 18.01M shares 17.97M shares 17.97M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q2 2018 Q1 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $15.80M $23.90M $52.80M
YoY Change -66.45% -54.73% -37.44%
Cash & Equivalents $15.76M $22.07M $21.20M
Short-Term Investments $0.00 $2.000M $31.70M
Other Short-Term Assets $900.0K $1.300M $1.600M
YoY Change -25.0% -18.75% -20.0%
Inventory $275.7K $418.2K $414.3K
Prepaid Expenses
Receivables $17.33K $12.63K $19.06K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $16.91M $25.64M $54.83M
YoY Change -65.54% -53.24% -36.59%
LONG-TERM ASSETS
Property, Plant & Equipment $180.0K $266.6K $479.3K
YoY Change -59.82% -44.36% -17.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $100.0K $64.80K
YoY Change 54.32% 0.0%
Total Long-Term Assets $306.6K $393.2K $670.7K
YoY Change -46.64% -41.37% -12.92%
TOTAL ASSETS
Total Short-Term Assets $16.91M $25.64M $54.83M
Total Long-Term Assets $306.6K $393.2K $670.7K
Total Assets $17.21M $26.03M $55.50M
YoY Change -65.32% -53.1% -36.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.145M $2.241M $818.8K
YoY Change -36.59% 173.74% -46.88%
Accrued Expenses $2.600M $1.800M $2.300M
YoY Change -16.13% -21.74% 53.33%
Deferred Revenue $0.00
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.793M $4.121M $3.218M
YoY Change -24.65% 28.03% 5.73%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $100.0K
YoY Change -100.0% -100.0% 547.58%
Total Long-Term Liabilities $0.00 $0.00 $100.0K
YoY Change -100.0% -100.0% 547.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.793M $4.121M $3.218M
Total Long-Term Liabilities $0.00 $0.00 $100.0K
Total Liabilities $3.803M $4.145M $3.278M
YoY Change -25.81% 26.47% 6.34%
SHAREHOLDERS EQUITY
Retained Earnings -$128.3M -$119.3M -$84.91M
YoY Change 36.91% 40.45% 81.65%
Common Stock $1.807K $1.798K $1.703K
YoY Change 4.51% 5.58% 6.37%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.184M -$3.316M $52.23M
YoY Change
Total Liabilities & Shareholders Equity $17.21M $26.03M $55.50M
YoY Change -65.32% -53.1% -36.39%

Cashflow Statement

Concept 2018 Q2 2018 Q1 2017 Q1
OPERATING ACTIVITIES
Net Income $111.2K -$381.5K -$8.268M
YoY Change -101.26% -95.39% -13.8%
Depreciation, Depletion And Amortization $60.00K $64.07K $91.37K
YoY Change -25.0% -29.88% 196.52%
Cash From Operating Activities -$8.260M -$9.412M -$8.226M
YoY Change 45.17% 14.43% -10.33%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $22.15K
YoY Change -100.0% -100.0% -79.35%
Acquisitions
YoY Change
Other Investing Activities $2.000M $12.12M $6.900M
YoY Change -91.59% 75.65% -302.35%
Cash From Investing Activities $2.000M $12.12M $6.881M
YoY Change -91.58% 76.13% -295.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 70.00K $54.91K $0.00
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -8.260M -$9.412M -$8.226M
Cash From Investing Activities 2.000M $12.12M $6.881M
Cash From Financing Activities 70.00K $54.91K $0.00
Net Change In Cash -6.190M $2.762M -$1.344M
YoY Change -134.29% -305.48% -89.4%
FREE CASH FLOW
Cash From Operating Activities -$8.260M -$9.412M -$8.226M
Capital Expenditures $0.00 $0.00 $22.15K
Free Cash Flow -$8.260M -$9.412M -$8.248M
YoY Change 45.94% 14.12% -11.13%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 dei Amendment Flag
AmendmentFlag
false
CY2018Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2018Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018Q1 dei Document Period End Date
DocumentPeriodEndDate
2018-03-31
CY2018Q1 dei Document Type
DocumentType
10-Q
CY2018Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001615219
CY2018Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
18013532 shares
CY2018Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2018Q1 dei Entity Registrant Name
EntityRegistrantName
Flex Pharma, Inc.
CY2017Q4 flks Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
3712221 USD
CY2018Q1 flks Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
1820292 USD
CY2017Q4 flks Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
2502400 USD
CY2018Q1 flks Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
985763 USD
CY2018Q1 flks Common Stock Numberof Votes
CommonStockNumberofVotes
1 vote
CY2018Q1 flks Contractwith Customer Refund Period
ContractwithCustomerRefundPeriod
P30D
CY2017Q1 flks Property And Equipment Purchases In Accrued Expense
PropertyAndEquipmentPurchasesInAccruedExpense
7100 USD
CY2018Q1 flks Property And Equipment Purchases In Accrued Expense
PropertyAndEquipmentPurchasesInAccruedExpense
0 USD
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2004440 USD
CY2018Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2241402 USD
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
10385 USD
CY2018Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
12631 USD
CY2017Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
107595 USD
CY2018Q1 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
131514 USD
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
227980 USD
CY2018Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
351192 USD
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1247 USD
CY2018Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
93 USD
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
140184630 USD
CY2018Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
141148465 USD
CY2017Q1 us-gaap Advertising Expense
AdvertisingExpense
665000 USD
CY2018Q1 us-gaap Advertising Expense
AdvertisingExpense
508000 USD
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1188752 USD
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
908940 USD
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3613410 shares
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3132478 shares
CY2017Q4 us-gaap Assets
Assets
34992772 USD
CY2018Q1 us-gaap Assets
Assets
26033095 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
34535137 USD
CY2018Q1 us-gaap Assets Current
AssetsCurrent
25639853 USD
CY2017Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
14129723 USD
CY2018Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
1999399 USD
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
38 USD
CY2018Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
93 USD
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1285 USD
CY2018Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 USD
CY2017Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
14130970 USD
CY2018Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
1999306 USD
CY2017Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
8191315 USD
CY2018Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
0 USD
CY2017Q4 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1
6 security
CY2018Q1 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1
0 security
CY2017Q4 us-gaap Cash
Cash
19186036 USD
CY2018Q1 us-gaap Cash
Cash
21948395 USD
CY2018Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
23947794 USD
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22542635 USD
CY2017Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21198279 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19312631 USD
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22074990 USD
CY2017Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1344356 USD
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2762359 USD
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17972166 shares
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17984811 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17797178 shares
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17980852 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
1780 USD
CY2018Q1 us-gaap Common Stock Value
CommonStockValue
1798 USD
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8279134 USD
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8221887 USD
CY2017Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
79106 USD
CY2018Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
83934 USD
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
58821 USD
CY2018Q1 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
58821 USD
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
39214 USD
CY2018Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
24509 USD
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
72188 USD
CY2018Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0 USD
CY2017Q1 us-gaap Depreciation
Depreciation
91367 USD
CY2018Q1 us-gaap Depreciation
Depreciation
64066 USD
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.49
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.46
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
874246 USD
CY2018Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
351823 USD
CY2018Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y11M12D
CY2018Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
5011000 USD
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4594716 USD
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3697287 USD
CY2017Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2018Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-366289 USD
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
236962 USD
CY2017Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6881 USD
CY2018Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-4514 USD
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-276168 USD
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1895468 USD
CY2017Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
37197 USD
CY2018Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-14705 USD
CY2017Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-7707 USD
CY2018Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 USD
CY2017Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-39810 USD
CY2018Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3297 USD
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
659732 USD
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
499023 USD
CY2017Q1 us-gaap Interest Income Operating
InterestIncomeOperating
77854 USD
CY2018Q1 us-gaap Interest Income Operating
InterestIncomeOperating
59593 USD
CY2017Q4 us-gaap Inventory Net
InventoryNet
431891 USD
CY2018Q1 us-gaap Inventory Net
InventoryNet
418196 USD
CY2017Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
17411 USD
CY2018Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
57629 USD
CY2017Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
414480 USD
CY2018Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
360567 USD
CY2017Q1 us-gaap Inventory Write Down
InventoryWriteDown
0 USD
CY2018Q1 us-gaap Inventory Write Down
InventoryWriteDown
0 USD
CY2017Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-2454 USD
CY2018Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-12231 USD
CY2017Q4 us-gaap Liabilities
Liabilities
5886884 USD
CY2018Q1 us-gaap Liabilities
Liabilities
4145024 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
34992772 USD
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
26033095 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5847670 USD
CY2018Q1 us-gaap Liabilities Current
LiabilitiesCurrent
4120515 USD
CY2017Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
14129723 USD
CY2018Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1999399 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
54913 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
6881236 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
12119933 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8225592 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9412487 USD
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-8268395 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-8223227 USD
CY2017Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8268395 USD
CY2018Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8223227 USD
CY2018Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
8588796 USD
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
8461402 USD
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8346249 USD
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8282820 USD
CY2017Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-10739 USD
CY2018Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
1340 USD
CY2017Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 USD
CY2018Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
3480 USD
CY2017Q1 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
2255 USD
CY2018Q1 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
2327 USD
CY2017Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
9607422 USD
CY2018Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
1997751 USD
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
22150 USD
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2018Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
777102 USD
CY2018Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1261232 USD
CY2017Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
16510076 USD
CY2018Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
14117184 USD
CY2017Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
732 USD
CY2018Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
500 USD
CY2017Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2018Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
54913 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
331040 USD
CY2018Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
266647 USD
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3914974 USD
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4680181 USD
CY2017Q4 us-gaap Restricted Cash
RestrictedCash
126595 USD
CY2018Q1 us-gaap Restricted Cash
RestrictedCash
126595 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-111079275 USD
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-119262285 USD
CY2017Q1 us-gaap Sales Discounts Goods
SalesDiscountsGoods
46000 USD
CY2018Q1 us-gaap Sales Discounts Goods
SalesDiscountsGoods
8000 USD
CY2017Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
240292 USD
CY2018Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
176255 USD
CY2017Q1 us-gaap Sales Revenue Net
SalesRevenueNet
242547 USD
CY2018Q1 us-gaap Sales Revenue Net
SalesRevenueNet
178582 USD
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1188752 USD
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
908940 USD
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1518128 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.90
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
35977 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
216350 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
813000 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
803600 USD
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3017213 USD
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2580491 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3128519 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.65
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.78
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
3017213 USD
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3128519 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.78
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.34
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
15.03
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.82
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.98
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1507813 USD
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y4M6D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M18D
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M29D
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y3M29D
CY2017Q1 us-gaap Shipping Handling And Transportation Costs
ShippingHandlingAndTransportationCosts
34000 USD
CY2018Q1 us-gaap Shipping Handling And Transportation Costs
ShippingHandlingAndTransportationCosts
25000 USD
CY2018Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
12645 shares
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
29105888 USD
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
21888071 USD
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16873512 shares
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17893912 shares
CY2018Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company's management evaluates its estimates, which include, but are not limited to, estimates related to clinical study accruals, estimates related to inventory realizability, stock-based compensation expense and amounts of expenses during the reported period. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</font></div></div>

Files In Submission

Name View Source Status
0001615219-18-000032-index-headers.html Edgar Link pending
0001615219-18-000032-index.html Edgar Link pending
0001615219-18-000032.txt Edgar Link pending
0001615219-18-000032-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
flks-20180331.xml Edgar Link completed
flks-20180331.xsd Edgar Link pending
flks-20180331_cal.xml Edgar Link unprocessable
flks-20180331_def.xml Edgar Link unprocessable
flks-20180331_lab.xml Edgar Link unprocessable
flks-20180331_pre.xml Edgar Link unprocessable
flks201833110-q.htm Edgar Link pending
flks2018331ex-311.htm Edgar Link pending
flks2018331ex-312.htm Edgar Link pending
flks2018331ex-321.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending